Neuro-Oncology: The Podcast

99 Folgen

1. Targeted therapy for BRAF-mutant pediatric glioma

   Vom: 17.6.2022
2. Early/evolving IDH wild-type glioblastoma

   Vom: 20.5.2022
3. PI3K signaling in IDH mutant gliomas

   Vom: 6.5.2022
4. Cell-free DNA from CSF in pediatric, adolescent and young adult patients

   Vom: 22.4.2022
5. Molecular determinants of neurocognitive deficits in glioma

   Vom: 8.4.2022
6. H3K27M cell-free tumor DNA tracking in response to ONC201 treatment for diffuse midline glioma

   Vom: 25.3.2022
7. Clinical trial accrual for women and minorities in neuro-oncology

   Vom: 11.3.2022
8. The clinical utility of next generation sequencing for IDHwt glioblastoma

   Vom: 11.2.2022
9. Trabectedin for recurrent grade 2 or 3 meningiomas

   Vom: 28.1.2022
10. Glioblastoma cell heterogeneity and plasticity

    Vom: 14.1.2022
11. Moleculary integrated grading for meningioma

    Vom: 24.12.2021
12. BOLD fMRI in IDH mutant gliomas

    Vom: 10.12.2021
13. Glioblastoma subtypes and response to Dasatinib

    Vom: 26.11.2021
14. Resection for recurrent brain metastases

    Vom: 12.11.2021
15. Incidental Meningiomas

    Vom: 29.10.2021
16. Immunosuppression in IDH mutant gliomas

    Vom: 15.10.2021
17. Immunotherapy for melanoma brain metastases

    Vom: 1.10.2021
18. DNA methylation profiles within the CATNON trial

    Vom: 17.9.2021
19. 18F FET PET in childhood CNS tumors

    Vom: 3.9.2021
20. Checkpoint blockade in atypical meningiomas

    Vom: 20.8.2021